Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precigen

1.54
+0.0000
Volume:402.33K
Turnover:613.86K
Market Cap:452.83M
PE:-3.27
High:1.56
Open:1.49
Low:1.48
Close:1.54
Loading ...

Precigen Inc. Files Amendment to 10-K Annual Report

Reuters
·
29 Apr

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

PR Newswire
·
16 Apr

Precigen, Inc.'s (NASDAQ:PGEN) Profit Outlook

Simply Wall St.
·
08 Apr

Stock Track | Precigen (PGEN) Soars 5.56% Following Strong Q1 Earnings and Pipeline Progress

Stock Track
·
21 Mar

Stock Track | Precigen Soars 5.56% Following Strong Q1 Earnings and Progress on Lead Asset

Stock Track
·
21 Mar

Analysts Are Bullish on Precigen Stock (PGEN) Amid Positive Pipeline Developments

TIPRANKS
·
21 Mar

Precigen Price Target Maintained With a $6.00/Share by Citizens Capital Markets

Dow Jones
·
20 Mar

Precigen Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Precigen’s Promising Outlook: Buy Rating Backed by Strategic Initiatives and PRGN-2012’s Potential FDA Approval

TIPRANKS
·
20 Mar

Precigen Reports Progress and Financial Results for 2024

TIPRANKS
·
20 Mar

Precigen FY 2024 GAAP EPS $(0.47), Inline, Sales $3.925M Miss $4.134M Estimate

Benzinga
·
20 Mar

Precigen Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
18 Mar

Precigen Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
14 Mar

Buy Rating for Precigen Driven by Promising Developments and Strong Market Potential of PRGN-2012

TIPRANKS
·
26 Feb

Precigen Says FDA Accepts for Priority Review Application for Recurrent Respiratory Papillomatosis Treatment

MT Newswires Live
·
25 Feb

Precigen Shares Jump 21.1% After FDA Grants Priority Review Status for Its Respiratory Tract Disease Treatment

THOMSON REUTERS
·
25 Feb

Precigen Shares Rise 16.6% Premarket After FDA Grants Priority Review Status for Its Respiratory Tract Disease Treatment

THOMSON REUTERS
·
25 Feb

Precigen Gets FDA Priority Review of Recurrent Respiratory Papillomatosis Treatment

Dow Jones
·
25 Feb

FDA Grants Priority Review to Precigen's Bla for Prgn-2012 for the Treatment of Adults With Recurrent Respiratory Papillomatosis With Pdufa Target Action Date Set for August 27, 2025

THOMSON REUTERS
·
25 Feb

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

PR Newswire
·
25 Feb